This document aims to recommend a basic framework for the preclinical safety evaluation of biotechnology-derived pharmaceuticals. It applies to products derived from characterised cells through the use of a variety of expression systems including bacteria, yeast, insect, plant, and mammalian cells.

Keywords: Non-clinical safety, biotechnology-derived pharmaceuticals, species selection, pharmacokinetics, toxicology

Current effective version - Revision 1

ICH: S6(R1): Preclinical safety evaluation of biotechnology - derived pharmaceuticals - Step 5

English (EN) (237.33 KB - PDF)View

External links

How useful do you find this page?

Your rating
Please do not include any personal data, such as your name or contact details. If you want to ask a question or request information from EMA, please Send a question to the European Medicines Agency.